ANTARES PHARMA, INC.
EWING, NJ

Antares Pharma, Inc. is a specialty pharmaceutical company that focuses on developing innovative drug-device combination products aimed at improving safety, efficacy, and patient compliance. Established in 1978 and publicly listed on NASDAQ since 2012, Antares Pharma designs self-injection pharmaceutical technologies with two FDA-approved product platforms: Vibex™ disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and pen devices. The company's portfolio targets therapeutic categories such as testosterone replacement, rheumatoid arthritis, women’s health, migraine management, type 2 diabetes, and anaphylaxis treatment. Over the past five years, Antares Pharma has launched four FDA-approved products: Otrexup™, Sumatriptan autoinjector, Zoma-Jet, and Gelnique. With more than 75 cumulative years of in-house product development experience, the company serves as a turn-key partner supporting all aspects of drug and device commercialization. The headquarters is located at 100 Princeton South, Suite 300, Ewing, NJ, while its mailing address is also based in Florida for regulatory purposes. Key officers include Stephen Knowles (VP) and Kristin Schwartzbauer (VP), with Nicole Labrosse serving as Secretary.